Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Prospektive klinische Untersuchung zur Bewertung der Sicherheit und Wirksamkeit von Juläine™ bei der Verbesserung der Gesäßhauterschlaffung bei Erwachsenen.

10. November 2026 aktualisiert von: Nordberg Medical AB

Prospektive klinische Untersuchung zur Bewertung der Sicherheit und Leistungsfähigkeit von Poly-L-Milchsäure - Juläine™ bei der Verbesserung der Gesäßhauterschlaffung bei Erwachsenen.

This study aims to evaluate the safety and effectiveness of Juläine™ (poly-L-lactic acid) injections for the treatment of buttock skin laxity.

Participants will be randomized to an immediate-treatment group or a delayed-treatment group. The immediate-treatment group will receive 2 to 3 treatment sessions over up to 2 months and will be compared with the delayed-treatment group during the control period; the delayed-treatment group will receive the same treatment after the delay.

The primary objective is to assess clinical improvement in buttock skin elasticity 6 months after the last treatment, defined as an increase in skin elasticity measured by a cutometer. Total study participation is up to 16 months, including follow-up.

This multicenter trial will be conducted in Brazil.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

This is an pivotal, open-label, two-arm, randomized, parallel-group, prospective clinical investigation conducted in Brazil to evaluate the safety and effectiveness of Juläine™ (poly-L-lactic acid) administered as subcutaneous injections for the treatment skin laxity in the buttock (gluteal) region in adults.

A total of 100 participants will be randomized to either an immediate-treatment group or a delayed-treatment group (delayed-start control). Participants in the immediate-treatment group will receive Juläine™ subcutaneous injections in 2 or 3 sessions at Day 0, Day 30, and Day 60. During this initial control period, outcomes in the immediate-treatment group will be compared with those in the delayed-treatment group, which will not receive treatment. After the control period, participants in the delayed-treatment group will receive the same Juläine™ regimen at Day 240, Day 270, and Day 300. Each participant will remain in the study for up to 16 months, excluding screening.

The primary efficacy endpoint is improvement in buttock skin elasticity 6 months after the last injection defined as an increase in global skin elasticity measured by a cutometer, with assessments at screening/baseline and at the primary post-treatment timepoint. The mean change in global skin elasticity measured by cutometer and Global Aesthetic Improvement Scale (GAIS) will also be evaluated, comparing groups during the control period.

Safety will be monitored through the collection of adverse events (AEs) through 240 days after randomization, with comparisons between groups during the control period. Adverse events will also be evaluated through extended follow-up, including up to 180 days in the overall study population and up to 480 days in the immediate-treatment group.

Studientyp

Interventionell

Einschreibung (Geschätzt)

100

Phase

  • Unzutreffend

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 55 Jahre (Erwachsene)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Adults aged 18 to 55 years;
  • Body Mass Index (BMI) between 18.5 and 24.95 kg/m².
  • Skin laxity of the gluteal region defined as sagging and reduced tightness of the skin.
  • Women of childbearing potential must be willing to abide by the contraceptive requirements
  • Ability to understand the study and provide informed consent, attend follow-up visits, and follow post-injection instructions.

Exclusion Criteria:

  • Pregnancy or breastfeeding, or planned pregnancy/lack of adequate contraception (through 8 weeks post-study);
  • Is planning to donate/bank or retrieve eggs (ova, oocytes) or donate sperm during the study or within 8-weeks of the end of participation of the clinical investigation.
  • Active infection, inflammation or lesions at or near the treatment site.
  • Acute infection at screening;
  • History of autoimmune disease;
  • Immune deficiencies;
  • History of hypertrophic scarring or keloid formation;
  • History of thrombosis in the lower limbs.
  • Previous surgical procedures involving the buttocks
  • Previous treatment with fillers, suspension threads, or fat injection in the treatment area within 18 months before randomization.
  • Previous aesthetic procedures in the treatment area, including radiofrequency, ultrasound, cryotherapy, neurotoxin, laser or light treatment, or chemical peel, within six months before randomization.
  • Previous topical or home therapy for cellulite in the treatment area within three months before randomization.
  • Hemorrhagic disease or ongoing use of antiplatelets/anticoagulant therapy.
  • Treatment with chemotherapy, immunosuppressive agents, systemic corticosteroids within 3 months before treatment (inhaled or ophthalmic corticosteroids are allowed).
  • Use of hormonal replacement therapy (HRT) unless the participant has been on a stable dose for at least 3 months prior to screening and does not plan to make any changes to the HRT regimen during the study period.
  • Use of topical corticosteroids, topical prescription retinoids in the treatment area within 1 month of the Baseline visit or systemic retinoid treatment within 6 months of the baseline visit, or plan to receive such treatment.
  • Use of other agents that inhibit collagen production.
  • Known allergy or hypersensitivity to any component of the investigational product.
  • History of herpes simplex rashes, malignant skin diseases, or any other serious dermatologic or systemic disease.
  • Presence of any condition that may impair wound healing (e.g., connective tissue disorders, severe malnutrition).
  • Planned or ongoing cosmetic procedures involving the buttocks or surrounding area during the period of clinical investigation.
  • Presence of any skin or local condition in the treatment area that could interfere with treatment administration, participant safety, or evaluation of study endpoints, including scars, fibrosis, tattoos, skin-pigmentation alterations, inflammation, lymphedema, or lipedema.
  • Participants actively taking GLP-1 medications with the intention of achieving additional weight loss (expected >10% during study) will be excluded. Participants on a stable GLP-1 regimen (≥3 months) for diabetes management or weight maintenance, with documented weight stability (±10% in past 6 months) and no planned or expected weight change >10%, may be included.
  • Any other medical or psychological condition that, in the opinion of the investigator, may interfere with participation in clinical research or evaluation of results.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Sofortbehandlungsgruppe

Juläine™ is a sterile injectable medical device composed of polylactic acid microspheres.

Sonstiges: Behandlungsgruppe mit verzögertem Beginn (Kontrollgruppe mit verzögertem Start)

Juläine™ is a sterile injectable medical device composed of polylactic acid microspheres.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Proportion of participants who achieve an improvement in gluteal skin elasticity
Zeitfenster: Baseline and 240 days after randomization

Proportion of participants achieving a clinically significant reduction in gluteal skin laxity at Day 240 after randomization, whereby a clinically significant reduction ("response") is defined as a relative increase of at least 10% in the gross elasticity measured by cutometer at Day 240 compared to baseline.

Baseline and 240 days after randomization

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Mean change in overall skin elasticity
Zeitfenster: Baseline and Day 240 after randomization.

Mean change in global medial skin elasticity measured by cutometer 180 days after treatment completion.

Baseline and Day 240 after randomization.
Global improvement based on Global Aesthetic Improvement Scale (GAIS) evaluated by investigator
Zeitfenster: Baseline and Day 240 after randomization.

Proportion of participants with at least a 1-point improvement in GAIS as rated by the investigator at Day 240 after randomization.

The GAIS scale values are:

  1. Very much improved
  2. Much improved
  3. Improved
  4. No change
  5. Worse

Where 1 represents the best outcome and 5 represents the worst.

Baseline and Day 240 after randomization.
Global improvement based on Global Aesthetic Improvement Scale (GAIS) evaluated by participant
Zeitfenster: Baseline and Day 240 after randomization.

Proportion of participants with at least a 1-point improvement in GAIS as rated by the participant at Day 240 after randomization

The GAIS scale values are:

  1. Very much improved
  2. Much improved
  3. Improved
  4. No change
  5. Worse

Where 1 represents the best outcome and 5 represents the worst.

Baseline and Day 240 after randomization.
Proportion of adverse events (AEs)
Zeitfenster: Occurring up to 240 days after the start of treatment, in both groups.

Proportion of adverse events (AEs) occurring up to 240 days after randomization.

Occurring up to 240 days after the start of treatment, in both groups.
Incidence and severity of Adverse events in the first 30 days
Zeitfenster: First 30 days after each Juläine™ administration, in all treated participants.

Incidence and severity of Adverse events in the first 30 days after each Juläine™ administration, in all treated participants.

First 30 days after each Juläine™ administration, in all treated participants.
Incidence and severity of AEs up to 240 days.
Zeitfenster: Up to 240 days after start of treatment in all treated participants.

Incidence and severity of AEs up to 240 days after start of treatment in all treated participants.

Up to 240 days after start of treatment in all treated participants.
Incidence and severity of AEs up to 480 days
Zeitfenster: Up to 480 days after start of treatment in the immediate-start group.

Incidence and severity of AEs up to 480 days after start of treatment in the immediate-start group.

Up to 480 days after start of treatment in the immediate-start group.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. Juni 2027

Primärer Abschluss (Geschätzt)

1. Januar 2028

Studienabschluss (Geschätzt)

1. Januar 2029

Studienanmeldedaten

Zuerst eingereicht

30. Dezember 2025

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

30. Dezember 2025

Zuerst gepostet (Tatsächlich)

12. Januar 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

16. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

10. November 2026

Zuletzt verifiziert

1. März 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • NB 15-TF-BZ-100-08F

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .